Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis

Advances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17

The objective of this study was to examine healthcare resource utilization (HRU) and costs associated with switching to another tumor necrosis factor alpha inhibitor (TNFi) therapy versus a non-TNFi therapy among patients with rheumatoid arthritis (RA) discontinuing use of an initial TNFi biologic therapy.

View abstract


Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A